EYPT EyePoint, Inc.

8-K Current Report

Filed: March 2, 2026

Health Care

Laboratory Analytical Instruments

EyePoint, Inc. (EYPT) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Phase 3 trials (COMO & CAPRI) for DURAVYU in diabetic macular edema now enrolling — first patients dosed March 2, 2026
• DME is a large market indication; Phase 3 initiation is a key de-risking milestone toward potential approval and commercialization

+1 more insights

Other EyePoint, Inc. 8-K Filings

8-K Mar 4, 2026

Get deeper insights on EyePoint, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.